A recent filing with the Securities and Exchange Commission has revealed that Matthew R. Kwietniak, the Chief Commercial Officer of Avid Bioservices, Inc. (NASDAQ:CDMO), has sold a portion of his company stock. On July 10, 2024, Kwietniak disposed of 444 shares of common stock at a price of $7.54 per share, amounting to a total transaction value of $3,347.
The transaction was part of a planned sale to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). According to the footnotes in the filing, this sale was not a discretionary trade by Kwietniak but a contractual obligation.
Avid Bioservices, Inc., based in Tustin, California, operates in the pharmaceutical preparations industry. The company, formerly known as Peregrine Pharmaceuticals Inc., focuses on providing development and manufacturing services for biotechnology and pharmaceutical companies.
The SEC filing also detailed the vesting of performance stock units (PSUs) and RSUs granted to Kwietniak. The PSUs are subject to the company achieving certain fiscal year revenue and adjusted pre-tax net income milestones over a three-year period, with the potential for the units to vest in thirds each fiscal year, contingent upon continuous service to the company.
In addition, Kwietniak was granted RSUs that are set to vest in sixteen equal quarterly installments over a four-year period, starting from dates in 2022, 2023, and 2024, respectively. These installments require continuous service to the company for vesting.
The recent transactions underscore the routine financial activities of company executives, providing insights into their stock ownership and compensation structure. For investors, such disclosures offer transparency into the actions of company insiders and their commitment to the company's future.
In other recent news, Avid Bioservices reported record revenues for the fourth fiscal quarter of 2024, with revenues slightly exceeding expectations by about 2%. The company's quarterly revenue increased by 8% year-over-year, reaching $43 million, despite a 6% decrease in full fiscal year revenues. Avid Bioservices also provided an optimistic revenue guidance for fiscal year 2025, projecting revenues between $160 million and $168 million, suggesting a significant year-over-year growth. KeyBanc Capital Markets and RBC Capital maintained their positive ratings on Avid Bioservices stock, despite lower order intake and EBITDA falling short. The companies emphasized the importance of bookings in evaluating Avid Bioservices' future performance and outlook. Avid Bioservices has expressed confidence in its growth, citing a surge in interest for its newly expanded capacity, especially from large pharmaceutical companies, and positive developments in the gene therapy sector. These recent developments are attributed to the launch of the company's new cell and gene therapy manufacturing facility and a trend towards onshoring drug manufacturing in the U.S.
InvestingPro Insights
Avid Bioservices, Inc. (NASDAQ:CDMO) has been navigating a challenging financial landscape, as reflected in recent data from InvestingPro. With a market capitalization of $507.38 million, the company's financial health is a critical factor for investors to consider. The InvestingPro Tips indicate that Avid Bioservices is grappling with weak gross profit margins, which stood at 5.23% for the last twelve months as of Q4 2024. This is a particularly relevant metric considering the company's focus on development and manufacturing services where margins can be indicative of operational efficiency.
Moreover, the company's Price / Book ratio was reported at 8.35, suggesting that the market values the company significantly higher than its net asset value. This could be a point of concern for value-focused investors, especially when coupled with the fact that analysts do not anticipate Avid Bioservices to be profitable this year. The company's negative P/E ratio of -3.61 reinforces this sentiment.
Investors should note that Avid Bioservices does not pay a dividend, which might be a consideration for those seeking income-generating investments. Additionally, the company has experienced a 6.27% decline in revenue over the last twelve months as of Q4 2024, which may raise questions about its growth prospects.
For those looking to delve deeper into the financial health and future prospects of Avid Bioservices, additional InvestingPro Tips are available. There are currently 4 additional tips listed on InvestingPro, which can be accessed at https://www.investing.com/pro/CDMO. For a more comprehensive analysis, readers can use the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.